Influence of blood sampling procedure on plasma concentrations of matrix metalloproteinases and their tissue inhibitors

Clinical and Experimental Pharmacology and Physiology

Volumn 35, Issue 4, 2008, Pages 464-469

  Rossignol, Patrick ^a,b   Cambillau, Michèle ^b   Bissery, Alvine ^b   Mouradian, Dikran ^b   Benetos, Athanase ^c   Michel, Jean Baptiste ^a   Plouin, Pierre François ^b   Chatellier, Gilles ^b   Jacob, Marie Paule ^a,d  

^a INSERM   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c Center for Preventive and Clinical Investigations   (France)

^d BICHAT HOSPITAL   (France)

Author keywords

Anticoagulant; Matrix metalloproteinases (MMP); Tissue inhibitors of metalloproteinases (TIMP)

Indexed keywords

CITRIC ACID; EDETIC ACID; GELATINASE A; GELATINASE B; HEPARIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ACCURACY; ADULT; ANTICOAGULATION; BLOOD SAMPLING; COMPARATIVE STUDY; CONFERENCE PAPER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FREEZE THAWING; HUMAN; MALE; NORMAL HUMAN; REPRODUCIBILITY; ZYMOGRAPHY;

ADULT; ANTICOAGULANTS; BLOOD SPECIMEN COLLECTION; FEMALE; FREEZING; HUMANS; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 40149107908     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2008.04897.x     Document Type: Conference Paper

References (21)

1. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: Structure, function, and biochemistry. Circ. Res. 2003 92 : 827 39.
2. Jacob MP. Extracellular matrix remodeling and matrix metalloproteinases in the vascular wall during aging and in pathological conditions. Biomed. Pharmacother 2003 57 : 195 202.
3. Moutsiakis D, Mancuso P, Krutzsch H, Stetler-Stevenson W, Zucker S. Characterization of metalloproteinases and tissue inhibitors of metalloproteinases in human plasma. Connect. Tissue Res. 1992 28 : 213 30.
4. Rossignol P, Cambillau M, Mouradian D, Plouin PF, Chatellier G, Jacob MP. Variations with time of plasma concentrations of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2. Thromb. Res. 2007 119 : 261 3.
5. Zucker S, Doshi K, Cao J. Measurement of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMP) in blood and urine: Potential clinical applications. Adv. Clin. Chem. 2004 38 : 37 85.
6. Blankenberg S, Rupprecht HJ, Poirier O et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003 107 : 1579 85.
7. Fontaine V, Jacob MP, Houard X et al. Involvement of the mural thrombus as a site of protease release and activation in human aortic aneurysms. Am. J. Pathol. 2002 161 : 1701 10.
8. Jung K, Nowak L, Lein M, Henke W, Schnorr D, Loening SA. Role of specimen collection in preanalytical variation of metalloproteinases and their inhibitors in blood. Clin. Chem. 1996 42 : 2043 5.
9. Jung K, Lein M, Laube C, Lichtinghagen R. Blood specimen collection methods influence the concentration and the diagnostic validity of matrix metalloproteinase 9 in blood. Clin. Chim. Acta 2001 314 : 241 4.
10. Mannello F. Effects of blood collection methods on gelatin zymography of matrix metalloproteinases. Clin. Chem. 2003 49 : 339 40.
11. Holten-Andersen MN, Murphy G, Nielsen HJ et al. Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer. Br. J. Cancer 1999 80 : 495 503.
12. Alby C, Ben Abdesselam O, Foglietti MJ, Beaudeux JL. Preanalytical aspects regarding the measurement of metalloproteinase-9 and tissue inhibitor or metalloproteinase-1 in blood. Clin. Chim. Acta 2002 325 : 183 6.
13. Makowski GS, Ramsby ML. Use of citrate to minimize neutrophil matrix metalloproteinase-9 in human plasma. Anal. Biochem. 2003 322 : 283 6.
14. Gerlach RF, Uzuelli JA, Souza-Tarla CD, Tanus-Santos JE. Effect of anticoagulants on the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. Anal. Biochem. 2005 344 : 147 9.
15. Badier-Commander C, Verbeuren T, Lebard C, Michel JB, Jacob MP. Increased TIMP/MMP ratio in varicose veins: A possible explanation for extracellular matrix accumulation. J. Pathol. 2000 192 : 105 12.
16. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986 1 : 307 10.
17. Jung K, Laube C, Lein M et al. Kind of sample as preanalytical determinant of matrix metalloproteinase 2 and 9 and tissue inhibitor of metalloproteinase 2 in blood. Clin. Chem. 1998 44 : 1060 2.
18. Sakamoto S, Sakamoto M, Goldhaber P, Glimcher MJ. Studies on the interaction between heparin and mouse bone collagenase. Biochim. Biophys. Acta 1975 385 : 41 50.
19. Holten-Andersen MN, Christensen IJ, Nielsen HJ et al. Measurement of the noncomplexed free fraction of tissue inhibitor of metalloproteinases I in plasma by immunoassay. Clin. Chem. 2002 48 : 1305 13.
20. Souza-Tarla CD, Uzuelli JA, Machado AA, Gerlach RF, Tanus-Santos JE. Methodological issues affecting the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. Clin. Biochem. 2005 38 : 410 14.
21. Mannello F. Effects of anticoagulants and cell separation media as preanalytical determinants on zymographic analysis of plasma matrix metalloproteinases. Clin. Chem. 2003 49 : 1956 7.